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Abstract 
 
 
Introduction: pain anticipated during injection of propofol was 
and still is a subject for study. Objectives: assessment of propofol 
injection pain in general and with regard to size and site of 
cannulation, gender and age. Methodology: this is a randomized 
prospective single blinded study in which 301 Sudanese patients 
were studied at KTH in the period between Oct. 2004 to Mar 2005.  
ASA class I and II non-premedicated patients between the age 18 and 
81years scheduled for various elective proceduresunder general 
anesthesia  were cannulated at either a large (antecubital) or Small 
(dorsal) vein with either size 20, 18 and 16 G iv cannula. Pain was 
graded according to verbal and numerical rating scales. Results & 
Conclusions: the incidence of propofol injection pain in general was 
found to be 43.19 %. The pain incidence decreased significantly when 
cannulating a large vein (69.01% compared to 30.9% for small veins). 
The use of a large size cannula significantly decrease the incidence of 
pain.  Gender and age appeared not to influence the incidence of pain 
in this study. We recommended that the use of a large size cannula 
inserted at a large vein is a useful mean to reduce the incidence of 
propofol I injection pain.  
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Introduction: 
 
Propofol is one of the great advances in the field of 
intravenous anesthesia owing to the optimal anesthetic 
conditions that can be achieved with its use. The use for 
application of LMA with minimal pressor effects or laryngeal 
irritation, TIVA, sedation in ICU patients and high risk patients 
greatly increased its popularity. However, its transient 
hyoptensie effect needs to be anticipated and cared for. 
Moreover, the pain it produces when injected intravenously 
remains to be a major disadvantage. 
 This study deals with the latter problem, which is 
propofol injection pain. Several studies were done in an attempt 
to quantify its magnitude and to minimize is extent by utilizing 
different measures. One of the local studies done by Dr. Ruba in 
2003 was concerned about the effect of pretreatment with 
labetalol (a short acting beta blocker) on propofol injection  
pain. She made an interesting observation that the use of large 
size cannulae was associated with reduced incidence of pain 
and she recommended a further study in this aspect. 
 This study is a continuation of Ruba’s study. It looks in 
the incidence of propofol induced pain in general and tests 
several hypotheses and variables that may change the 
occurrence of pain or modifies its severity. 
 Though different pharmacologic measures are being 
applied successfully to reduce propofol injection pain, non- 
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pharmacologic ones could prove worthy and justify an effort; at 
last pharmacological measures are never devoid of side effect. 
It is not expected that technical measures could be the absolute 
salvage out of this problem; nevertheless, they may reduce the 
need and dose of pharmacological measures, putting in mind 
that the definitive solution is a new generation of propofol that 
is devoid of this unwarranted side effect.  
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Literature Review: 
 
 History : 
Propofol (Diprivan®) is the most recent intravenous 
anesthetic to be introduced into clinical practice. Work in the 
early 1970s on substituted derivatives of phenol with hypnotic 
properties resulted in the development of 2, 6-di-isopropofol 
(Fargen,1988) . The first clinical trial by Kay and Rolly reported 
in 1977 confirmed the potential of propofol as an anesthetic 
induction agent (Kay, Rolly, 1977). Propofol is insoluble in 
water and therefore was initially prepared with Cremophor EL 
(BASF A.G.). Because of anaphylactoid reactions associated 
with Cremophor EL in this early formulation of propofol, the 
drug was reformulated in an emulsion (Briggs, 1982). Since then 
Propofol has been used for induction and maintenance of 
anesthesia as well as for sedation for short periods (to 
supplement regional anesthesia; sedoanlgesia) and for longer 
periods (for ICU patients). 
 
Physicochemical Characteristics 
Propofol is one of a group of alkylphenols that have 
hypnotic properties in animals(James,1980). The alkylphenols 
are oils at room temperature and are insoluble in aqueous 
solution but are highly lipid-soluble. The injectable Emulsion is 
a sterile, nonpyrogenic emulsion containing 10 mg/mL of 
propofol suitable for intravenous administration. Propofol is 
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chemically described as 2,6-diisopropylphenol and has a 
molecular weight of 178.27. The present formulation consists of 
1 percent (wt/vol) propofol, 10 percent soybean oil, 2.25 
percent glycerol, and 1.2 percent purified egg phosphatide. It 
has a pH of 7 and a pKa of 11. Propofol appears as a slightly 
viscous, milky white substance. Propofol is available as a 1 
percent solution in 20-ml clear glass ampules and 50-ml vials. 
The formulation also contains soybean oil (100 mg/mL), 
glycerol (22.5 mg/mL), egg lecithin (12 mg/mL); and disodium 
edetate (0.005%); with sodium hydroxide to adjust pH. 
Disodium edetate is added to retard the rate of growth of 
microorganisms in the event of accidental extrinsic 
contamination. It is stable at room temperature and is not light-
sensitive. If a dilute solution of propofol is required, it is 
compatible with 5 percent dextrose in water (Astra Zeneca 
formula, 2004). 
 
Metabolism  
Propofol is rapidly metabolized in the liver by conjugation 
to glucuronide and sulfate to produce water-soluble 
compounds, which are excreted by the kidneys (Simons, 1985). 
Less than 1 percent propofol is excreted unchanged in urine, 
and only 2 percent is excreted in feces (Simons, 1985). The 
metabolites of propofol are thought not to be active. Because 
clearance of propofol exceeds hepatic blood flow, extrahepatic 
metabolism or extrarenal elimination has been suggested. 
Extrahepatic metabolism has been confirmed during the 
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anhepatic phase of patients receiving a transplanted liver 
(Veroli, Gray, 1992). The lungs do not seem to be the site of this 
extrahepatic metabolism. 
 
Pharmacokinetics 
 
The pharmacokinetics of propofol following a wide range 
of doses as well as following continuous infusions have been 
evaluated by numerous investigators (Simons 1985, Adam 1983, 
Kay 1986, Gepts1987, Kirkpatrick1988, Shafer1988) and have 
been described by both two- and three-compartmental models . 
Intravenous injection of a therapeutic dose of propofol 
produces hypnosis rapidly with minimal excitation, usually 
within 20 - 40 seconds from the start of an injection (the time 
for one arm-brain circulation). As with other rapidly acting 
intravenous anesthetic agents, the half-time of the blood-brain 
equilibration is approximately 1 to 3 minutes, and this accounts 
for the rapid induction of anesthesia (Astra Zeneca formula , 
2004). 
 
Following a single bolus injection, whole blood propofol 
levels decrease very rapidly as a result of both redistribution 
and elimination. The initial distribution half-life of propofol is 
2 to 8 minutes (Simons1985, Kay1986). In studies using a two-
compartment model, the elimination half-life has varied from 
1.0 to 3 hours (Schuttler1985, Shafer1988). Studies using a 
three-compartment model have given initial and slow 
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distribution half-lives of 1 to 8 minutes and 30 to 70 minutes 
and an elimination half-life of 4 to 23.5 hours (Gepts1986, 
Kay1987). This longer elimination half-life is indicative of a 
deep compartment with limited perfusion, which results in a 
slow return of propofol back to the central compartment. Owing 
to the very rapid clearance of propofol from the central 
compartment, the slow return of propofol from this deep 
compartment contributes little to the initial rapid decrease in 
propofol concentrations. The context-sensitive half-time for 
propofol for infusions of up to 8 hours is less than 40 minutes 
(Hughes 1992). As the required decrease in concentration for 
awakening following anesthesia or sedation with propofol is 
generally less than 50 percent, recovery from propofol will 
remain rapid even following prolonged infusions. The volume 
of distribution of the central compartment has been calculated 
as 20 to 40 L and the volume of distribution at steady state as 
150 to 700 L (Simons 1985, Adam 1983, Shafer 1986). The 
clearance of propofol is extremely high-1.5 to 2.2 L/min 
(Simons 1985, Adam 1983, Shafer 1986). This exceeds hepatic 
blood flow, and extrahepatic metabolism has been 
demonstrated (Veroli 1992, Gray 1992). The Keo  for propofol is 
0.291 min-1 and the t1/2 Keo  is 2.4 minutes based on 
suppression of the EEG. The time to peak effect is 92 seconds 
(Dyck 1991).  
The pharmacokinetics of propofol may be altered by a 
variety of factors (e.g., gender, weight, pre-existing disease, 
age, and concomitant medication).  Women have a higher  
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volume of distribution and higher clearance rates, but the 
elimination half-life is similar for males and females (Key 1986, 
Shafer 1988). The elderly have decreased clearance rates but a 
smaller central compartment volume. Children have a larger 
central compartment volume (50 percent) and a more rapid 
clearance (25 percent) (Marsh 1992). Hepatic disease appears to 
result in a larger steady state and central compartment 
volumes; clearance is unchanged but the elimination half-life is 
slightly prolonged (Servin 1987). The effect of fentanyl 
administration on propofol pharmacokinetic parameters is 
controversial. Some studies suggest that fentanyl may reduce 
both intercompartmental and total body clearance  rates as well 
as volumes of distribution (Benoni 1990). In a separate study 
fentanyl did not alter propofol pharmacokinetics following a 
single dose of both drugs (Gill 1990).  In vitro studies on human 
hepatocytes, propofol inhibited in a dose-dependent manner the 
enzymatic degradation of both sufentanil and alfentanil (Janicki 
1992). Propofol kinetics are unaltered by renal disease (Morcos 
1985).  
 
Pharmacology: 
 
         Effects on the Central Nervous System  
     Propofol is primarily a hypnotic. The exact mechanism 
of its action has not yet been fully elucidated; however, 
evidence suggests that it acts by enhancing the function of the 
GABA-activated chloride channel. Although propofol acts via 
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the GABA receptor, its action is pressure-reversible, and it 
adheres to the correlation exhibited by other general anesthetics 
between anesthetic potency and octanol/water distribution 
coefficient (Tonner 1992). Unlike barbiturates, propofol is not 
antianalgesic (Briggs 1982).  The onset of hypnosis following 
doses of 2.5 mg/kg is rapid (one arm-brain circulation) (Major 
1981, Rolly 1985). The ED50  of propofol is 1 to 1.5 mg/kg 
following a bolus (Glass 1988, Major 1981). The duration  of 
hypnosis is dose-dependent, being 5 to 10 minutes following 2 
to 2.5 mg/kg (Adam 1982, Major 1981). Age markedly affects 
the ED95  induction dose of propofol, being highest at ages less 
than 2 (ED95  2.88 mg/kg) and decreasing with increasing age 
(Aun 1992). At subhypnotic doses propofol will provide 
sedation and amnesia (Wilson 1988, Veselis 1982). Propofol 
infusions of at least 2 mg/kg/h were necessary to provide 
amnesia in unstimulated volunteers (Zacny 1992). During 
surgical procedures very high infusion rates may be necessary 
to prevent awareness if propofol is used as the sole anesthetic 
(Glass 1993).  Propofol alters mood following short surgical 
procedures to a lesser extent than thiopental. Propofol also 
tends to produce a general state of well-being. Hallucinations, 
sexual fantasies, and opisthotonos have been reported 
following propofol administration (Nelson 1988, Cameron 
1987) . 
        The effect of propofol on the EEG as assessed after 
2.5 mg/kg followed by an infusion demonstrates an initial 
increase in α-rhythm followed by shift to δ and β frequency. 
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High infusion rates produce burst suppression. EEG power 
analysis indicates that amplitude increases after induction but 
is thereafter unaltered at propofol blood concentrations of 3 to 
8 µg/ml. At propofol concentrations greater than 8µg/ml, 
amplitude markedly decreases, with periods of burst sup-
pression. There is a strong correlation between the logarithm of 
blood concentration of propofol and the percentage of d activity 
content, and there is an inverse correlation with percentage of b 
activity content (Yate 1986).  
     The effect of propofol on epileptogenic EEG activity is 
controversial. Initial studies in mice indicate that propofol 
neither induced convulsions nor provided anticonvulsant 
activity. (Glen 1985) Several more recent reports have shown in 
a variety of  models a direct anticonvulsant effect of propofol, 
which is dose-dependent (Heavner 1992).It is regarded as the 
first choice in status epilepticus. There have also recently been 
reports of addiction and tolerance developing to propofol 
following either repeated anesthetics or prolonged infusions 
(days) (Boyle 1990, Follette 1992).  
   Propofol will decrease ICP in patients with either 
normal or elevated ICP. The addition of small doses of fentanyl 
and of supplemental doses of propofol ablates the rise of ICP 
secondary to endotracheal intubation. Normal cerebral 
reactivity to carbon  dioxide and autoregulation are maintained 
during a propofol infusion. In patients with elevated ICP, the 
decrease in ICP (30 to 50 percent) is associated with significant 
decreases in cerebral perfusion pressure (Ravussin) and 
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therefore may not be beneficial. Propofol acutely reduces 
intraocular pressure by 30 to 40 percent. As compared with 
thiopental, propofol produces a greater decrease in intraocular 
pressure, and following a small second dose it is more effective 
in preventing a rise in intraocular pressure secondary to 
succinylcholine and endotracheal intubation (Mirakhur).  
     The propofol Cp50  for loss of response to verbal 
command is 3.5 mg/ml (Vuyk 1992). The propofol Cp50  (arterial 
whole blood concentration) to prevent movement on skin 
incision is 16 mg/ml. This is markedly reduced by increasing 
concentrations of fentanyl (Smith, 1992). The propofol Cp50  for 
skin incision when combined with benzodiazepine 
premedication (lorazepam 1 to 2 mg) and 66 percent nitrous 
oxide is 2.5 mg/ml (venous). This concentration is reduced to 
1.7 mg/ml when morphine (0.15 mg/kg) rather than lorazepam 
is used for premedication (Spelina 1986). The concentration of 
propofol (when combined with 66 percent nitrous oxide) 
required during minor surgery varies from 1.5 to 4.5 mg/ml 
(Shafer 1988) and that for major surgery varies from 2.5 to 6 
mg/ml (Sanderson 1988). Awakening usually occurs below a 
concentration of 1.6 mg/ml and orientation below 1.2 mg/ml. 
Age affects the propofol concentration required to provide 
adequate anesthesia (Shafer 1988).  
 
Effects on the Respiratory System  
       Propofol affects the respiratory system in a manner 
qualitatively similar to the action of barbiturates (Sanderson 
 19 
1988). Apnea occurs after an induction dose of propofol; the 
incidence and duration of apnea appear dependent on dose, 
speed of injection, and concomitant premedication. An 
induction dose of propofol results in a 25 to 30 percent 
incidence of apnea. The apnea occurring with propofol 
however, may be prolonged to more than 30 seconds. The 
incidence of prolonged apnea (longer than 30 seconds) is 
further increased by addition of an opiate, either as a 
premedication or just prior to induction and is greater with 
propofol than with other commonly used intravenous induction 
agents (Gold 1987). The onset of apnea is usually preceded by 
marked tidal volume reduction and tachypnea. Following a 2.5 
mg/kg induction dose of propofol, respiratory rate is 
significantly decreased for 2 minutes and minute volume is 
significantly reduced for up to 4 minutes, which indicates a 
more prolonged effect of propofol on tidal volume than on 
respiratory rate (Taylor 1986) . 
    A maintenance infusion of propofol (100 mg/kg/min) 
results in a 40 percent decrease in tidal volume and a 20 percent 
increase in respiratory frequency, with an unpredictable change 
in minute ventilation. Doubling the infusion rate from 100  to 
200 µg/kg/min causes a further moderate decrease in tidal 
volume (455 to 380 ml) but no change in respiratory frequency. 
The ventilatory response to carbon dioxide is also decreased 
during a maintenance infusion of propofol. At 100 µg/kg/min 
there is a 58 percent reduction in the slope of the carbon 
dioxide response curve. This is similar to the 50 percent 
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depression of carbon dioxide responsiveness measured with 1 
MAC of halothane or after a brief infusion of 3 µg/kg/min of 
thiopental. Doubling the infusion rate (and presumably the 
blood level) of propofol results in only minimal further 
decrease in carbon dioxide responsiveness. This is in contrast to 
halothane, with which use of twice the MAC results in halving 
the carbon dioxide response. Propofol 1.5 to 2.5 mg/kg results 
in an acute (13 to 22 percent) rise in PaCO2  and a decrease in 
pH.  PaO2  does not change significantly. These changes are 
similar to those seen following an induction dose of thiopental. 
During a maintenance infusion of propofol (54 µg/kg/min) 
PaCO2  is moderately increased from 39 to 52 mmHg. Doubling 
this infusion rate does not result in a further increase in PaCO2. 
Propofol (50 to 120µg/kg/min) also depresses the ventilatory 
response to hypoxia  .Propofol induces bronchodilation in 
patients with chronic obstructive pulmonary disease. Propofol, 
however, does not appear to provide as effective 
bronchodilating properties as halothane (Goodman 1987, Knill 
1978).  
 
Effects on the Cardiovascular System: 
       The cardiovascular effects of propofol have been 
evaluated following its use both for induction and for 
maintenance of anesthesia (Aun 1984, Grounds 1985, Al-
Khudhairi 1982). The most prominent effect of propofol is a 
decrease in arterial blood pressure during induction of 
anesthesia. Independently of the presence of cardiovascular 
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disease, an induction dose of 2 to 2.5 mg/kg produces a 25 to 40 
percent reduction of systolic blood pressure. Similar changes 
are seen in mean and diastolic pressure. The decrease in arterial 
pressure is associated with a decrease in cardiac output/cardiac 
index (about 15 percent), and systemic vascular resistance (15 
to 25 percent). Left ventricular stroke work index is also 
decreased (by about 30 percent). In patients with valvular heart 
disease, pulmonary artery and pulmonary capillary wedge 
pressure are also reduced, which implies that the resultant 
decrease in pressure is due to a decrease in both preload and 
afterload. The decrease in systemic pressure following an 
induction dose of propofol appears to be due to both 
vasodilation and myocardial depression. Both the myocardial 
depressant effect and the vasodilation appear to be dose and 
plasma concentration dependent. The vasodilatory effect of 
propofol appears  to be due both to a reduction in sympathetic 
activity and to a direct effect on intracellular smooth muscle 
Ca++ mobilization (Ebert 1992).  
Heart rate does not change significantly after an 
induction dose of propofol. It has been suggested that propofol 
either resets or inhibits the baroreflex, thus reducing the 
tachycardic response to hypotension (Ebert 1992).  
         During the maintenance of anesthesia with a 
propofol infusion, systolic pressure remains between 20 and 30 
percent below preinduction levels. In patients allowed to 
breathe room air during a maintenance infusion of 100 
µg/kg/min propofol, there is a significant decrease in systemic 
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vascular resistance (30 percent), but cardiac index and stroke 
index are unaltered. In contrast, in patients receiving a narcotic 
premedication and nitrous oxide with an infusion of propofol 
(54 and 108 µg/kg/min) for maintenance during surgery, 
systemic vascular resistance is not significantly decreased from 
baseline, but cardiac output and stroke volume are(Claeys 
1983). These differences in the effect of propofol on systemic 
vascular resistance may be due to the presence of nitrous oxide 
or surgical stimulation. Increasing the infusion rate of propofol 
from 54 to 108 µg/kg/min (blood concentration 2.1 to 4.2 
µg/ml) produces only a slightly greater decrease in arterial 
blood pressure (about 10 percent). The peak plasma 
concentrations obtained following a bolus dose are 
substantially higher than those seen with a continuous infusion. 
As the vasodilatory and myocardial depressant effects are 
concentration dependent, the decrease in blood pressure from 
propofol during the infusion phase is much less than that seen 
following an induction bolus . 
     
              Other Effects  
Propofol (like thiopental) does not potentiate neuromuscular 
blockade produced by both nondepolarizing and depolarizing 
neuromuscular blocking agents (Nightingale 1985). Propofol 
produces no effect on the evoked electromyogram or twitch 
tension however, good intubating conditions after propofol 
alone have been reported. The  lipid emulsion per se reduces in 
vitro platelet aggregation (Aviram 1989). Recently 
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anaphylactoid reactions to the present formulation of propofol 
have been reported. In at least some of the patients the immune 
response was entirely due to propofol and not to the lipid 
emulsion. A high percentage of the patients developing the 
anaphylactoid response to propofol had a previous history of 
allergic responses. In patients with multiple drug allergies, 
propofol should be used with caution (Laxenaire 1992). In most 
people the new preparation does not trigger histamine release 
(Astra Zeneca formula 2004). 
Propofol also possesses significant antiemetic activity at low 
(subhypnotic) doses. It has been used successfully to treat 
postoperative nausea in a bolus dose of 10 mg. Propofol as an 
infusion of 1 mg/kg/h has also provided excellent antiemetic 
action following chemotherapy. Propofol at subhypnotic doses 
has also been reported to relieve cholestatic pruritus, as well as 
pruritus induced by spinal opiates (Borgeat 1984).  
 
 
Uses 
 
  Induction and Maintenance of Anesthesia 
          Propofol is suitable for both the induction and 
maintenance of anesthesia. The induction dose varies from 1.0 
to 2.5 mg/kg and the ED95  in unpremedicated adult patients is 
2.25 to  2.5 mg/kg (Cummings 1992). Premedication with an 
opiate and or a benzodiazepine tends to markedly reduce the 
induction dose. Increasing age also reduces the dose of 
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propofol required to induce anesthesia (Cummings). A dose of 1 
mg/kg (with premedication) to 1.75 mg/kg (without 
premedication) is recommended for inducing anesthesia in 
patients over 60 years of age and is increased (2.0 to 3.0 mg/kg) 
for induction in children, primarily because of pharmacokinetic 
differences (Astra Zeneca formula).  
Propofol, when used for induction of anesthesia in shorter 
procedures, results in a significantly quicker recovery and 
earlier return of psychomotor function as compared with 
thiopental or methohexital, irrespective of the agent used for 
maintenance of anesthesia (Astra Zeneca formula 2004). The 
incidence of nausea and vomiting when propofol is used for 
induction is also markedly less than following the other 
intravenous induction agents, probably because of the 
antiemetic properties of propofol (Astra Zeneca formula 2004). 
Propofol, because of its pharmacokinetics, provides a rapid 
recovery and is thus superior to barbiturates for maintenance of 
anesthesia, and it appears equal to enflurane and 
isoflurane(Glass 1988). Propofol can be given as intermittent 
boluses or as a continuous infusion for maintenance following a 
satisfactory induction  dose, a bolus of 10 to 40 mg is needed 
every few minutes to maintain anesthesia. As these doses need 
to be given frequently, it is more suitable to administer 
propofol as a continuous infusion (Astra Zeneca formula 2004) . 
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                   Sedation  
             Propofol has been evaluated for sedation during 
surgical procedures and for patients receiving mechanical 
ventilation in the ICU (Mackenzie 1987, Grounds 1985). 
Propofol by continuous  infusion provides a readily titratable 
level of sedation and a rapid recovery once infusion is 
terminated irrespective of the duration of the infusion. In a 
study of patients sedated in the ICU for 4 days with propofol, 
recovery to consciousness was rapid (about 10 minutes). Both 
the rate of recovery and decrease in plasma concentration were 
similar at 24 and at 96 hours, when the infusion was 
discontinued. Also, the plasma concentrations required for 
sedation and for awakening were similar at 24 and 96 hours, 
which implies that tolerance to propofol, did not occur (Beller 
1988). There have been more recent reports of tolerance with 
propofol. Infusion rates required for sedation to supplement 
regional anesthesia in healthy patients are half or less than half 
of those required for general anesthesia (i.e., 30 to 60 
µg/kg/min). In elderly patients (over 65 years) and sicker 
patients the infusion rates that are necessary are markedly 
reduced. Thus, it is important to individually titrate the 
infusion to the desired effect (Astra Zeneca formula 2004). 
  
Side Effects and Contraindications 
Induction of anesthesia with propofol is associated with 
several side effects. These include pain on injection, myoclonus, 
apnea, a decrease in arterial blood pressure, and very rarely, 
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thrombophlebitis of the vein into which propofol is injected. 
Pain on injection is less than or equal to that with etomidate, 
equal to that with methohexital, and greater than after 
thiopental. Myoclonus occurs more frequently following 
propofol than following thiopental but less frequently than 
following etomidate or methohexital.  
Apnea following induction with propofol is common. The 
incidence of apnea may be similar to that obtained following 
thiopental or methohexital; however, propofol produces a 
greater incidence of apnea lasting longer than 30 seconds. The 
addition of an opiate increases the incidence of apnea, 
especially prolonged apnea.  
The most significant side effect on induction is the 
decrease in systemic blood pressure. Addition of an opiate just 
prior to induction of anesthesia appears to augment the 
decrease in arterial blood pressure. Perhaps slow 
administration and lower doses in adequately prehydrated 
patients may attenuate the decrease in arterial blood pressure. 
Conversely, the effects of laryngoscopy and endotracheal 
intubation and the increases in mean arterial pressure, heart 
rate, and systemic vascular resistance are less following 
propofol than thiopental.  
Propofol should only be administered to intubated, mechanically 
ventilated adult patients in the Intensive Care Unit (ICU) to provide 
continuous sedation and control of stress responses. In this setting, 
propofol should be administered only by persons skilled in the medical 
management of critically ill patients and trained in cardiovascular 
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resuscitation and airway management. Propofol is not indicated for use in 
pediatric ICU sedation since the safety of this regimen has not been 
established. The Drug is not recommended for obstetrics, including 
cesarean section deliveries. It crosses the placenta, and as with other 
general anesthetic agents, the administration of propofol may be 
associated with neonatal depression. (Astra Zeneca formula, 2004.) 
Propofol is not recommended for use in nursing mothers because it 
has been reported to be excreted in human milk, and the effects of oral 
absorption of small amounts of propofol are not known .Propofol is 
contraindicated in patients with a known hypersensitivity to the drug or 
its components, or when general anesthesia or sedation are 
contraindicated and in patients with airway obstruction (Astra Zeneca 
formula, 2004. Smith,  2001). 
 
Pain induced by intravenous injection: 
 
Pain physiology: is generally defined as unpleasant 
sensation followed by protective reflex. Its receptors are free 
nerve endings found everywhere in the body. The nerve fibers 
are classified into fast Aδ and slow C fibers. Its pathway is 
through lateral spinothalamic, spinoreticular tracts. Perception 
of pain is integrated in the thalamus and analysis of its nature 
occurs in the cortex. Pain could sharp ( somatic) or dull 
(visceral) and could be acute or chronic. Many 
neurotransmitters are involved. Pain could be inhibited 
peripherally or centrally (Smith,  2001). 
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Pain measurement: pain is measured to provide 
information about severity and cause and to determine or 
evaluate treatment. The visual analogue scale is one of the most 
widely used measures of pain intensity and consists of a 10 cm 
line marked at one end with ( no pain) and at the other (worst 
pain ever)or similar phrases. It is a useful clue to the 
effectiveness of treatment, it is simple and easy to use but does 
not differentiate sensory from affective components of pain. 
The verbal and numerical rating scales (none, mild, 
moderate and severe) are simple tools to measure pain intensity 
and are sensitive to detect improvement. Numerical pain rating 
scales are similar to visual analogue scale but replace the line 
with numbers from zero to 10(Smith,  2001).  
McGILL pain questionnaire provides more accurate 
measure of the pain experience, distinguishes sensory and 
affective nature of pain. it consist of twenty subgroups, each 
contains 2 – 6 adjectives that are qualitatively similar but 
increase in intensity. The patient indicates the pain by using 
one word from each group which is then analysed (Smith,  2001).  
Measurement of pain in children is a bit different and 
involves the child parents nursing staff and some deals with 
behavioral changes (Smith,  2001).  
A number of drugs cause pain during IV injection. In 
addition to propofol there is etomidate, methohextal, althesin 
and diazepam. The cuase of this pain is not known ,but 
possibilities include speed of injection, concentration of the 
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drug or its solvent, allergy ,vein caliber, age , gender, …etc 
(Smith,  2001) 
The cause of pain upon injection of propofol is not well 
understood, but it is related to concentration and solvent 
characteristics. Doenicke et al, hypothesized that the concentration of 
propofol in the aqueous phase may be the most important variable 
responsible for the pain experienced during injection of the drug. The 
concentration of propofol in the aqueous phase (18.57 micrograms/mL) 
can be decreased by increasing the fat content of the solvent. To test this 
hypothesis, they randomly allocated 36 patients to three groups, each 
receiving a different formulation of propofol. Group A received 20 mL of 
propofol alone in a commercial preparation (Diprivan(R) with 10 mL of 
saline); Group B, 20 mL of propofol to which 5 mL of long-chain 
triglyceride (LCT) fat emulsion and 5 mL of saline and been added; and 
Group C, 20 mL of propofol and 10 mL of LCT fat emulsion. The propofol 
emulsion was injected over 30-60 s into a dorsal vein of the hand. Patients 
reported pain during injection as none, mild, moderate, or severe (almost 
intolerable). In Group A, 8 of 12 patients reported moderate or severe pain 
upon injection whereas in Group C only mild pain was reported by 6 of 12 
patients. They suggested that a smaller concentration of propofol in the 
aqueous phase of the emulsion reduces pain on injection. With the 
addition of more lipid (10 mL), a higher percentage of propofol is absorbed 
by fat particles. If solvents that permit a smaller concentration of the drug 
in the aqueous phase of oil-in-water emulsions were used for propofol and 
other drugs that cause pain on injection, pain would be reduced and 
patient satisfaction may be increased (Doenicke, 1996). 
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Pain induced by intravenous injection was noticed by 
many observers. Bachmann and colleagues assessed incidence 
and intensity of pain on intravenous injection of propofol in an 
emulsion of medium-chain/long-chain triglycerides in patients 
undergoing different elective surgical interventions. The new 
solvent was used for induction of general anesthesia. 
Spontaneous pain reactions and pain elicited upon questioning 
were assessed. Patients were asked to grade the pain as mild, 
moderate or severe. Co-medication with sedative or analgesic 
drugs, size of the intravenous cannulae, site of injection and 
administration as a single bolus or in divided doses were 
recorded. The overall incidence of pain, in this study was 28.4 
percent. Twelve percent of the patients complained 
spontaneously (severe pain) and 16.4 percent reported pain 
after questioning (mild and moderate). Pain intensity was 
graded as mild by 16.7 percent of the patients. The incidence of 
pain was significantly less when using an antecubital vein 
compared with a forearm or dorsal hand vein (p = 0.017 
spontaneously reported pain, p = 0.001 pain elicited upon 
questioning). The number of patients complaining 
spontaneously of pain was significantly lower (p = 0.006) for 
large size than for small and medium size cannulae. They 
concluded that the incidence of pain on injection of a medium-
/long-chain triglyceride propofol formulation was 28.4% with 
16.7% of the patients reporting mild pain. The use of an 
antecubital vein or a large size venous cannula appears to 
reduce the injection pain (Bachmann, 2003).  
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Briggs et al used di-isopropyl phenol as main agent for short 
procedures, they observed that pain on injection was uncommon when the 
drug was given into an antecubital vein, but occurred in 39% of patients 
when injected to the back of the hand or wrist (Briggs, 1981). 
Hynynen compared pain on injection of three anaesthetic induction 
agents, thiopentone, methohexitone and propofol (diisopropyl phenol), 
administered into a vein on the dorsum of the hand or wrist.  He studied 
32 premedicated patients undergoing elective surgery. The pain was rated 
as none, mild or severe. A 1% emulsion formulation of propofol (ICI 35 
868) (2 mg kg-1) and methohexitone (2 mg kg-1) induced pain significantly 
more often, in 100% and 80% of patients, respectively, than thiopentone (4 
mg kg-1), 0%. The pain was rated as severe more often in patients 
receiving propofol (67%, P less than 0.01 vs thiopentone) than in those 
anaesthetized with methohexitone (20%) or thiopentone (0%). It is 
concluded that the fat emulsion form of propofol, when injected into a 
peripheral vein, frequently induces severe pain (Hynynen, 1985). 
Ruba found in the control group of the study conducted to assess the 
effect of labetolol on the incidence of injection pain of propofol an overall 
incidence of pain of 38% and that the incidence of pain increase with 
decrease of the size of the cannula (Ruba, 2003). 
Scott and others assessed eight modes of administration of propofol 
in order to minimize the pain of injection. An intravenous bolus injection 
in the antecubital fossa was the only approach that caused no pain. When 
administered intravenously in the dorsum of the hand the pain score and 
the number of patients who experienced pain was reduced significantly by 
mixing the agent with lignocaine when compared with a bolus injection. 
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Slowing the speed of injection caused the greatest discomfort. An indirect 
biochemical mechanism for the pain is proposed (Scott, 1988) 
McCulloch and colleagues assessed pain on injection of the 
emulsified formulation of di-isopropylphenol (propofol, 'Diprivan')  in 120 
unpremedicated patients and comparison made with thiopentone. A high 
incidence of pain (37.5%) was found using dorsal hand veins, but use of 
forearm veins showed only a 2.5% incidence of pain (McCulloch,1985).  
Larsen et al, performed a monocentre, controlled, randomised, 
double-blind study to compare the pain produced by intravenous injection 
of a new propofol preparation (propofol-MCT/LCT) with standard 
propofol in patients undergoing elective surgical procedures. A total of 184 
non-premedicated patients received either 1% propofol prepared in a 
mixture of medium and long chain triglycerides (Propofol-MCT/LCT, 
Propofol- Lipuro, B. Braum Melsungen AG) or standard 1% propofol 
prepared exclusively in long chain triglycerides (Propofol-LCT; 
Disoprivan, AstraZeneca) into a vein of the dorsal hand for induction of 
anaesthesia. Patients receiving propofol-MCT/LCT had a significantly 
lower incidence of pain on injection compared to the standard propofol 
group (37% vs. 64%) with the intensity of pain also being less severe 
(Larsen, 2001). 
Onaka and colleagues compared both incidence and 
severity of pain during injection of 20 ml of 1% propofol with 
or without lignocaine in elderly and young ages in a 
randomized prospective double blinded study. They found that 
elderly suffered pain with same incidence and severity as 
young and lignocaine marked reduced both incidence and 
severity of the pain (Onaka, 1998). 
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Pleym et al found that males are more sensitive than females to 
propofol onset of action but there were no significant difference in 
injection induced pain. They concluded that It may therefore be necessary 
to decrease the propofol dose by 30-40% in males compared with females 
in order to achieve similar recovery times (Pleym, 2003).  
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Objectives: 
 
 
1. To study the incidence of propofol injection pain. 
2. To study the effect of intravenous cannula size on the incidence 
of propofol injection pain. 
3. To study the effect intravenous cannulation site (i.e. small or 
large vein) on the incidence of propofol injection pain. 
4. To study the effect of gender variation on the incidence of 
propofol injection pain. 
5. To study the effect of age on the incidence of propofol injection 
pain. 
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Patients & Methods: 
 
 This is a descriptive, prospective, randomized single blinded study 
on the incidence of pain during propofol injection in general and under 
variable conditions. The study was conducted at KTH during the 
period from October 2004 to March 2005. Three hundred and one 
patients undergoing various types of elective procedures under general 
anesthesia were selected randomly. All patients were ASA class I and 
II. All patients under the age of 18, pregnant or who have any 
contraindication to propofol use were excluded from this study. 
Propofol was used as induction agent only. 
 After pre-operative assessment the patients were consented. An 
intravenous cannula size 20, 18 or 16 G was inserted in a vein on the 
dorsum of the hand (small vein) or cubital fossa (large vein) under 
standard aseptic technique. The site and size of the cannula was chosen 
randomly. All patients received only atropine prior to injection of 
propofol. A standard dose 2mg/Kg of propofol 1% was given 
intravenously within 90 to 120 sec. Pain was assessed by facial 
expression of the patient and asking the patient whether he feels the 
pain during injection. The patient was asked to grade the severity of 
pain felt during injection. The score was expressed in 4 grades where 1 
means no pain, 2 mild pain, 3 moderate pain and 4 severe pain. 
Monitoring was started preoperatively and maintained throughout the 
intra- and postoperative period with minimum required monitors; 
pulse oximetry, NIBP, temp. and ECG. 
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 The data were collected in a data form (appendix 1) and entered in a 
spread sheet of Excel software (Microsoft 2003). The data were analyzed 
using EPI6 program and results were recorded. 
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Results: 
 
In this study 301 patients underwent induction with propofol 
intravenously through different cannulae sizes and sites. There were 151 
males and 150 females’ (Fig. 1). The age ranged between 18 years and 81 
years. The median age of this group 38 years and the mean age 40 years (± 
15.16 years). Those patients were divided into three age groups: young (18 
– 39 years), middle age (40 – 59 years) and elderly (more than 60 years) 
(Fig. 2). Young age group was populated with 111(36.9%) patients 
61(54.9%) were males and 50 (45.1%) were females. The middle age group 
contained 125 (41.5%) patients, 46 (36.8%) were males and 79 (63.8%) were 
females. The elderly age group contained 65 (21.6%) patients of them 44 
(67.7%) were males and 21(33.3%) were females (Table 1). 
One hundred forty six (48.5%) patients underwent cannulation of a 
large vein at the cubital fossa while 155 (51.5%) were cannulated at a small 
vein at the dorsum of the hand (Fig. 3). 
 
The incidence of pain: 
In this study 43.19% (130/301) of the patients felt pain during 
propofol injection and 56.81% (171/301) of the population of this study felt 
no pain. Of the 130 patients who experienced pain 65 (50%) had mild pain 
(31 males, 34 females), 30 (23.08%) felt moderate pain (16 males, 14 
females) and 35 (26.92%) felt severe pain (17 males, 18 females). Of the 171 
patients who felt no pain during propofol injection, 87 were males and 84 
were females (Table 2, Fig. 4).  
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The incidence of pain and the site of the cannula: 
When data concerning patients who felt no pain were further 
analysed 53 (30.99%) patients received  propofol through a cannula 
inserted in the dorsum of the hand (small vein), while 118 (69.01 %) 
received the drug though a cannula inserted at the antecubital fossa ( large 
vein); p value 0.0078452 (Fig. 5) . Of this group   51 (29.83%) size 20 
cannulae, 72 (42.10 %) size 18 and 48 (28.07%) size 16 cannula were used; p 
value was 0.02383421 (Table 3).   
 
In the group of patients who felt pain during propofol injection (n = 
130), 38 (29.23%) were cannulated in a large vein (antecubital fossa) and 92 
(70.77%) were cannulated in a small vein (dorsum of the hand) p value 
0.00823161 (Fig. 6). In forty nine (37.7%) patients size 20 cannulae were 
used, 29 (22.3%) size 18 cannulae were used and in 52(40.0%) size 16 
cannulae were used, p value was 0.0476534 (Table 4). 
 
The Size of the Cannula: 
One hundred intravenous cannulae were used for each size (there 
were 101 for size 18 G.). Considering size 20 G cannulae, 31 (31%) were 
inserted for males and 69 (69%) females(Fig. 7). Fifty six percent (56/100) 
were inserted in a vein in the antecubital fossa while 44% (44/100) were 
inserted in a vein in the dorsum of the hand (Fig. 8). Forty four percent 
(44/100) the patients felt no pain, 20 % (20/100) felt mild pain, 12 % 
(12/100) had moderate pain while 24% (24/100) severe pain during 
propofol injection.  Total number of patients who felt pain in this 
population was 56 (56%) patients. p value was 0.0262163 (Fig. 9). A further 
observation was noticed that of the 44 patients who felt no pain when size 
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20 cannula was used, 39 (88.6%) of these cannulae were inserted in the 
antecubital fossa, p value 0.00163277. 
 
Regarding size 18 intravenous cannula; 43 (42.6%) were inserted in a 
vein in the antecubital fossa and 58 (57.4%) were inserted in a vein in the 
dorsum of the hand (Fig. 10). Sixty eight (67.3%) were females and 33 
(32.7%) were males (Fig. 11). Sixty four (63.4%) of the patients of this group 
felt no pain, while 36.6% (36) felt pain of them 23(22.8%) felt mild pain, 
11(10.9%) felt moderate pain and 3(2.9%) felt severe pain. p value was 
0.0348531 (Fig. 12). 
 
Regarding size 16 intravenous cannula; 47 (47%) were inserted in a 
vein in the antecubital fossa and 53 (53%) were inserted in a vein in the 
dorsum of the hand (Fig. 13). Fifty one (51%) females and 49 (49%) were 
males (Fig. 14). Sixty three (63%) of the patients of this group felt no pain, 
26(26%) felt mild pain, 6 (6%) felt moderate pain and 5 (5%) felt severe 
pain. p value was   0.003124523 (Fig. 15). 
 
The incidence of pain according to the age group: 
Sixty three (56.75%) patients in the young age group (n = 111) felt 
pain during propofol injection, 41 (32.8%) patients in the middle age group 
(n =125) and 26 (40%) patients of the elderly age group. p value was 
0.07123422 (Fig. 16).   
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The incidence of pain according to sex: 
In this study 64 (49.20%) males (n = 151) felt pain during propofol 
injection and 66 (50.70%) females (n = 150) felt pain. p value was 0.0832441 
(Fig. 17).   
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Fig 1 
 
Sex Distribution in 301 Patients Who Underwent Assessment of 
Propofol Injection Pain  
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Fig 2 
 
 
Age Distribution in  301 Patients Who Underwent Assessment of 
Propofol Injection Pain  
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Fig 3 
 
 
Site of Cannulation in  301 Patients Who Underwent Assessment of 
Propofol Injection  Pain  
 
 
 
51%
49%
large vein small vein
 
 46 
 
 
 
 
 
 
 
 
Fig 4 
 Pain Incidence and Sex Frequency in 301 Patients Who Underwent 
Assessment of Propofol Injection  Pain  
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Fig 5 
Type of vein used in patients who felt no pain during propofol 
injection (No. 171) 
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p value = 0.0078452 
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Fig 6 
Type of vein used in patients who felt  pain during propofol 
injection (No. 130) 
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p value = 0.00823161 
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Fig 7 
 Distribution of sex in 100 Patients Who Underwent Assessment of 
Propofol Injection Pain with a size 20 IV Cannula 
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Fig 8 
Distribution of site of Cannula in 100 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 20 IV Cannula  
 
 
 
 
 
 
44%
56%
Dorsum Antecubital
 
 51 
 
 
 
 
 
 
 
 
 
 
 
Fig 9 
Distribution of type of pain in 100 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 20 IV Cannula  
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p value = 0.0262163 
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Fig 10 
 
Distribution of site of Cannula in 101 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 18 IV Cannula  
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Fig 11 
 Distribution of sex in 101 Patients Who Underwent Assessment of 
Propofol Injection Pain with a size 18 IV Cannula 
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Fig 12 
 
 
Distribution of type of pain in 101 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 18 IV Cannula  
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p value = 0.0348531 
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Fig 13 
Distribution of site of Cannula in 100 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 16 IV Cannula  
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Fig 14 
 
 Distribution of sex in 100 Patients Who Underwent Assessment of 
Propofol Injection Pain with a size 16 IV Cannula 
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Fig 15 
 
 
Distribution of type of pain in 100 Patients Who Underwent 
Assessment of Propofol Injection Pain with a size 16 IV Cannula  
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p value = 0.003124523 
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Fig 16 
 
The incidence of pain according to the age group in 130 patients who 
felt pain during propofol intravenous injection 
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p value = 0.07123422 
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Fig 17 
The incidence of pain according to sex in 130 who felt pain during 
propofol injection 
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p value = 0.0832441 
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Table 1 
 
Sex distribution with in each age group in 301 Patients Who 
Underwent Assessment of Propofol Injection Pain 
 
 
 
 
AGE 
GROUP 
NUMBER PERCENT MALES PERCENT FEMALES PERCENT 
Young 
18 - 39 
111 36.9 61 54.9 50 45.1 
Meddle 
40 - 59 
125 41.5 46 36.8 79 63.2 
Elderly 
60 - 81 
65 21.6 44 67.7 21 33.3 
Total 301  151  150  
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Table 2 
 
Pain Incidence and Sex Frequency in 301 Patients Who Underwent 
Assessment of Propofol Injection Pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAIN TYPE NO (%) FEMALES  MALES (%) 
No pain 171 (58.81) 84 (56.00) 87 (57.62) 
Mild 065 (21.59) 34 (22.67) 31 (20.53) 
Moderate 030 (09.96) 14 (09.33) 16 (10.59) 
Severe 035 (11.64) 18 (12.00) 17 (12.26) 
Total 301 (100.0) 150 (100.0) 151 (100.0) 
 62 
 
 
 
 
 
 
Table 3 
 
 
Type of IV cannula used in patients who felt no pain during 
propofol injection (No. 171) 
 
 
 
 
 
 
 
 
 
 
 
 
p value =  0.02383421 
 
SIZE OF IV 
CANNULA 
NO OF PT. % 
20 51 29.83 
18 72 42.10 
16 48 28.07 
Total 171 100 
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Table 4 
 
 
Type of IV cannula used in patients who felt pain during propofol 
injection (No. 130) 
 
 
 
 
 
 
 
 
 
 
 
 
p value = 0.0476534 
 
SIZE OF IV 
CANNULA 
NO OF PT. % 
20 49 37.70 
18 29 22.30 
16 52 40.00 
Total 130 100 
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Discussion: 
 
 Propofol injection pain remains a major complication that makes 
its use an unfavorable experience to quite a number of patients. This study 
evaluated the incidence of pain associated with its injection in 301 
Sudanese patients who underwent induction with propofol through 
different cannula sizes and sites. The number of patients in this study was 
among the large series in literature (Doenicke, 1996. Hynynen, 1985, 
Larsen, 2001).  
 
There were almost equal numbers of males (n =151) and females 
(n=150) (Fig. 1). All age groups were adequately represented. The age 
ranged between 18 years and 81 years with median age of 38 years and a 
mean of 40 years (± 15.16 years) (Fig. 2, Table 1). Comparable number of 
patients underwent cannulation at the cubital fossa and the dorsum of the 
hand (Fig. 3). 
 
The accepted incidence of pain is around 40% (Smith, 2001). 
Bachmann reported a lower incidence of 28.4%in non-
premedicated patients (Bachmann, 2003), while Hynynen reported 
an incidence of 100 %(Hynynen,1985). In this study the incidence of 
propofol injection pain in general was found to be 43.19%. This difference 
of incidence may be explained by a number of factors. The small number 
of patients used in Hynynen study (32 patients) (Hynynen,1985) and the 
type of propofol used in Bachmann study(Bachmann, 2003). On the 
other hand Briggs reported almost similar pain incidence (Briggs, 1981).  
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Pain severity is almost equal between sex groups. Of the 130 patients 
who experienced pain 65 (50%) had mild pain (31 males, 34 females), 30 
(23.08%) felt moderate pain (16 males, 14 females) and 35 (26.92%) felt 
severe pain (17 males, 18 females). Bachmann reported 12%of severe pain 
and 16.7 % mild pain (Bachmann, 2003) (Table 2, Fig. 4). 
 
The incidence of pain in this study was significantly reduced (p 
value 0.0078452) when a large vein was used. Studying the data 
concerning patients who felt no pain (n =171), 53 (30.99%) patients 
received propofol through a cannula inserted in the dorsum of the hand 
(small vein), while 118 (69.01 %) received the drug though a cannula 
inserted at the antecubital fossa (large vein) (Fig. 5). This goes along with 
the findings of Bachmann, Briggs and Hynynen (Bachmann, 2003. 
Hynynen, 1985. Briggs, 1981).  
The larger the size of the cannula the less is the incidence of pain. Of 
this group   51 (29.83%) size 20 cannulae, 72 (42.10 %) size 18 and 48 
(28.07%) size 16 cannula were used; p value was statistically significant ( p 
value 0.02383421 ) (Table 3).  This finding is further augmented when we 
look at the figures obtained on patient who felt pain (n = 130) where 38 
(29.23%) were cannulated in a large vein (antecubital fossa) and 92 
(70.77%) were cannulated in a small vein (dorsum of the hand) p value 
was 0.00823161 (Fig 6). This complies with the findings of Scott, McCulloch 
and Larsen (Scott, 1988. McCulloch, 1985. Larsen, 2001). 
 
The size of the cannula affected the incidence of pain in this study. 
Equal number of cannulae used was with no comparable difference in the 
site of cannulation (Figs 9, 12, 15).  The incidence of pain increased with 
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use of small gauge cannulae (56 (56%) patients. p value was 0.0262163 (Fig. 
9) for size 20 – 36.6% p value was 0.0348531 (Fig. 12) for size 18 – 47% p 
value was   0.003124523 (Fig. 15) for size 16). An interesting finding was 
observed when this data were further studied. Of the   44 patients who felt 
no pain when size 20 cannula was used, 39 (88.6%) of these cannulae were 
actually inserted in the antecubital fossa, p value 0.00163277 this conferred 
to Bachmann and Ruba findings (Bachmann, 2003.  Ruba 2003). From 
this observation one can derive that it is not just the caliber of the vein 
used but also the velocity of flow of blood in that vein in question. This 
coincide well with the finding that pain incidence is significantly less in 
antecubital fossa (proximal vein with increase velocity of flow). 
 
In this study the age of patients does not affect the incidence of pain. 
(p value was 0.07123422) (Fig. 16). This goes with Onaka (Onaka, 1987). 
Again the difference in sex does not affect the incidence of pain. Almost 
equal number of males (42.38%) and females (44%) felt pain (p value was 
0.0832441 (Figs 4, 17).   This comply with the findings of Pleym 
(Pleym,2003)  
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Conclusions: 
 
In this study it is concluded that: 
 
• The overall incidence of propofol injection pain was 43.19%. 
• The site of the cannula with least incidence of pain was the 
cubital fossa. 
• The larger the size of the cannula used the less incidence of 
pain. 
• The sex difference does not affect the incidence of pain. 
• The age difference does not affect the incidence of pain. 
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Recommendation:  
 
• Antecubital fossa is ideal for administration of propofol 
intravenously. 
 
• Large size cannulae should be chosen to minimize the incidence 
of pain. 
 
• The effect of velocity of blood flow rather than just the caliber 
of vein should be further assessed. 
 
• Further studies to confirm these findings. 
 
 70 
 
 
 
 
 
Chapter V 
 71 
References: 
 
 
1. Fargen RJ, Diprivan (propofol): a historical prospective; Seminal 
Anesth 7:11, 1988. 
2. Kay B, Rolley G, ICI 35 868, new intravenous induction agent; Acta 
Anaesthesiol Belg 28: 303 ,1977. 
3. Briggs LP, Clarke RSJ, Watkins J, An adverse reaction to the 
administration of disoprofol (Diprivan). Anesthesia 37:1099 1982. 
4. James R, Glen JB, Synthesis, biological evaluation, and preliminary 
structure-activity considerations of a series of alkylphenols as 
intravenous anesthetic agents; J Med Chem 23:1350 1980. 
5. Astra Zeneca Formula, internet web site (http://www.diprivan -
us.com/anesthesia) 
6. Simons PJ, Cockshott ID, Douglas EJ et al, Blood concentrations, 
metabolism and elimination after a subanesthetic intravenous dose 
of 14C-propofol (Diprivan) to male volunteers, abstracted; Postgrad 
Med J 61:64 1985 
7. Veroli P, O'Kelly B, Bertrand F et al, Extrahepatic metabolism of 
propofol in man during the anhepatic phase of orthotopic liver 
transplantation; Br J Anaesth 68:183 1992. 
8. Gray PA, Park GR, Cockshott ID et al, Propofol metabolism in man 
during the anhepatic and reperfusion phases of liver 
transplantation; Xenobiotica 22:105 1992. 
 72 
9. Adam HK, Briggs LP, Bahar M et al , Pharmacokinetic evaluation of 
ICI 35 868 in man. Single induction doses with different rates of 
injection; Br J Anaesth 55:97 1983. 
10. Kay NH, Sear JW, Upington J et al,  Disposition of propofol in 
patients undergoing surgery. A comparison in men and women; Br J 
Anaesth 58:1075 1986. 
11. Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS,  
Pharmacokinetics of propofol (Diprivan) in elderly patients; Br J 
Anaesth 60:146 1988. 
12. Gepts E, Camu F, Cockshott ID, Douglas EJ,  Disposition of propofol 
administered as constant rate intravenous infusions in humans; 
Anesth Analg 66:1256 1987. 
13. Shafer A, Doze VA, Shafer SL, White PF, Pharmacokinetics and 
pharmacodynamics of propofol infusions during general anesthesia; 
Anesthesiology 69:348 1988. 
14. Schuttler J, Stoeckel H, Schwilden H, Pharmacokinetic and 
pharmacodynamic modeling of propofol (Diprivan) in volunteers 
and surgical patients ; Postgrad Med J 61:53 1985. 
15. Hughes MA, Jacobs JR, Glass PSA , Context-sensitive half-time in 
multicompartment pharmacokinetic models for intravenous 
anesthesia; Anesthesiology 76:334 1992. 
16. Dyck JB, Varvel J, Hung O, Shafer SL, The pharmacokinetics of 
propofol vs age; Anesthesiology 75:A315 1991.  
17. Marsh B, White M, Morton N, Kenny GNC,  Pharmacokinetic model 
driven infusion of propofol in children; Br J Anaesth 67:41 1991 
 73 
18. Servin F, Desmonts JM, Farinttir et al, Pharmacokinetics of propofol 
given as a continuous infusion in a cirrhotic patient. Preliminary 
results; Ann Fr Anesth Reanim 6:228 1987 
19. Benoni G, Cuzzolin L, Gilli E et al, Pharmacokinetics of propofol: 
influence of fentanyl administration, abstracted; Eur J Pharmacol 
183:1457 1990 
20. Gill SS, Wright EM, Reilly CS, Pharmacokinetic interaction of 
propofol and fentanyl: single bolus injection study; Br J Anaesth 
65:760 1990. 
21. Janicki PK, James MFM, Erskine WAR, Propofol inhibits enzymatic 
degradation of alfentanil and sufentanil by isolated liver 
microsomes in vitro ; Br J Anaesth 68:311 1992 
22. Morcos WE, Payne JP, The induction of anaesthesia with propofol 
(Diprivan) compared in normal and renal failure patients ; Postgrad 
Med J 61:62 1985 
23. Tonner PH, Poppers DM, Miller KW, The general anesthetic potency 
of propofol and its dependence on hydrostatic pressure; 
Anesthesiology 77:926 1992. 
24. Briggs LP, Dundee JW, Bahar M, Clarke RSJ, Comparison of the 
effect of diisopropylphenol (ICI 35 868) and thiopentone on response 
to somatic pain; Br J Anaesth 54:307 1982 
25. Major E, Verniquet AJW, Waddell TK et al, A study of three doses of 
ICI 35 868 for induction and maintenance of anaesthesia ; Br J 
Anaesth 53:267 1981 
26. Rolly G, Versichelen L, Huyghe L, Mungroop H,  Effect of speed of 
injection on induction of anesthesia using propofol; Br J Anaesth 
57:743 1985. 
 74 
27. Glass P, Ginsberg B, Hawkins ED et al, Comparison of sodium 
thiopental/isoflurane to propofol (delivered by means of a 
pharmacokinetic model-driven device) for the induction, 
maintenance, and recovery from anesthesia; Anesthesiology 69:A575 
1988. 
28. Adam HK, Kay B, Douglas EJ, Blood disoprofol levels in 
anesthetized patients. Correlation of concentration after single or 
repeated doses with hypnotic activity; Anaesthesia 37:536 1982. 
29. Aun CST, Short SM, Leung DHY, Oh TE, Induction dose response of 
propofol in unpremedicated children; Br J Anaesth 68:64 1992. 
30. Wilson E, Mackenzie N, Grant IS, A comparison of propofol and 
midazolam by infusion to provide sedation in patients who receive 
spinal anaesthesia; Anaesthesia 43:91 1988 
31. Veselis RA, Reinsel RA, Wronski M et al, EEG and memory effects of 
low dose infusions of propofol; Br J Anaesth 69:246 1992 
32. Zacny JP, Lichtor JL, Coalson DW et al, Subjective and psychomotor 
effects of subanesthetic doses of propofol in healthy volunteers; 
Anesthesiology 76:696 1992. 
33. Glass PSA ,Prevention of awareness during total intravenous 
anesthesia; Anesthesiology 78:399 1993 
34. Nelson VM Hallucinations after propofol, letter; Anaesthesia 43:170 
1988 
35. Cameron AE, Opisthotonis again, letter; Anaesthesia 42:1124 1987 
36. Yate PM, Maynard DE, Major E et al, Anaesthesia with ICI 35 868 
monitored by the cerebral function analyzing monitor (CFAM); Eur J 
Anaesthesiol 3:159 1986 
 75 
37. Glen JB, Hunter SC, Blackburn TP, Wood P, Interaction studies and 
other investigations of the pharmacology of propofol (Diprivan); 
Postgrad Med J 61:7 1985 
38. Heavner JE, Arthur J, Zou J et al , Propofol vs. thiopental for treating 
bupivicaine induced seizures in rats; Anesthesiology 77:A802 1992. 
39. Boyle WA, Shear JM, White PF, Schuller D, Tolerance and 
hyperlipemia during long term sedation with propofol; 
Anesthesiology 73:A245 1990 
40. Follette JW, Farley WJ, Anesthesiologist addicted to propofol; 
Anesthesiology 77:817 1992 
41. Ravussin P, Guinard JP, Ralley F, Thorin D , Effect of propofol on 
cerebrospinal fluid pressure and cerebral perfusion pressure in 
patients undergoing craniotomy; Anaesthesia 43:37 1988 
42. Mirakhur RK, Shepherd WFI, Darrah WC, Propofol or thiopentone: 
effects on intraocular pressure associated with induction of 
anaesthesia and tracheal intubation (facilitated with 
suxamethonium) ; Br J Anaesth 59:431 1987 
43. Vuyk J, Engbers FHM, Lemmens HJM et al, Pharmacodynamics of 
propofol in female patients; Anesthesiology 77:3 1992 
44. Smith C, McEwan AI, Jhaveri R et al, Reduction of propofol Cp50 by 
fentanyl; Anesthesiology 77:A340 1992 
45. Spelina KR, Coates DP, Monk CR et al, Dose requirements of 
propofol by infusion during nitrous oxide anaesthesia in man. I: 
Patients premedicated with morphine sulphate; Br J Anaesth 58:1080 
1986 
46. Sanderson JH, Blades JF, Multicentre study of propofol in day case 
surgery; Anaesthesia 43:70 1988. 
 76 
47. Gold MI, Abraham EC, Herrington C, A controlled investigation of 
propofol, thiopentone and methohexitone; Can J Anaesth 34:478 1987. 
48. Taylor MB, Grounds RM, Dulrooney PD, Morgan M, Ventilatory 
effects of propofol during induction of anesthesia. Comparison with 
thiopentone ; Anaesthesia 41:816 1986. 
49. Goodman NW, Black AMS, Carter JA, Some ventilatory effects of 
propofol as sole anesthetic agent; Br J Anaesth 59:1497 1987 
50. Knill RL, Clement JL, Gelb AW Ventilatory responses mediated by 
chemoreceptors in anaesthetized man; Adv Exp Med Biol 99:67 1978 
51. Aun C, Major E, The cardiorespiratory effects of ICI 35 868 in 
patients with valvular heart disease; Anaesthesia 39:1096 1984 
52. . Grounds RM, Twigley AJ, Carli F et al, The haemodynamic effects 
of thiopentone and propofol ; Anaesthesia 40:735 1985 
53. Al-Khudhairi D, Gordon G, Morgan M, Whitwam JG, Acute 
cardiovascular changes following disoprofol. Effects in heavily 
sedated patients with coronary artery disease ; Anaesthesia 37:1007 
1982 . 
54. Ebert TJ, Muzi M, Goff DR, Kampine JP, Does propofol really 
preserve baroreflex function in humans ?  ; Anesthesiology 77:A337 
1992. 
55. Claeys MA, Gepts E, Camu F, Haemodynamic changes during 
anaesthesia induced and maintained with propofol; Br J Anaesth 60:3 
1983. 
56. Aviram M, Deckelbaum RJ, Intralipid infusion into humans reduces 
in vitro platelet aggregation and alters platelet lipid composition ; 
Metabolism 38:343 1989 
 77 
57. Laxenaire MC, Mata Bermejo E, Moneret Vautrin DA, Gueant JL 
Life-threatening anaphylactoid reactions to propofol ('Diprivan) ; 
Anesthesiology 77:275 1992 
58. Borgeat A, Wilder Smith OHG, Saiah M, Rifat K, Subhypnotic doses 
of propofol possess antiemetic properties; Anesth Analg 74:539 1992 
59. Cummings GC, Dixon J, Kay NH et al, Dose requirements of ICI 35, 
868 (propofol, Diprivan) in a new formulation for induction of 
anaesthesia; Anaesthesia 39:1168 1984 
60. Glass P, Ginsberg B, Hawkins ED et al, Comparison of sodium 
thiopental/isoflurane to propofol (delivered by means of a 
pharmacokinetic model-driven device) for the induction, 
maintenance, and recovery from anesthesia; Anesthesiology 69:A575 
1988 
61. Mackenzie N, Grant IS ,Propofol for intravenous sedation; 
Anaesthesia 42:3 1987 
62. Grounds RM, Lalor JM, Lumley J et al, Propofol infusion for 
sedation in the intensive care unit: preliminary report ; Br Med J 
294:397 1985 
63. Beller JP, Pottecher T, Lugnier A et al, Prolonged sedation with 
propofol in ICU patients. Recovery and blood concentration changes 
during periodic interruptions in infusion ; Br J Anaesth 61:583 1988 . 
64. Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. Reducing 
pain during propofol injection: the role of the solvent. Anesth 
Analg.;82:472 1996 
65. Bachmann-Mennenga B, Ohlmer A, Heesen M.Incidence of pain 
after intravenous injection of a medium-/long-chain triglyceride 
 78 
emulsion of propofol. An observational study in 1375 patients. 
Arzneimittelforschung; 2003. 53:621. 
66. Briggs LP, Clarke RS, Dundee JW, Moore J, Bahar M, Wright PJ. Use 
of di-isopropyl phenol as main agent for short procedures. Br J 
Anaesth.53:1197 1981. 
67. Hynynen M, Korttila K, Tammisto T. Pain on i.v. injection of 
propofol (ICI 35 868) in emulsion formulation. Short 
communication. Acta Anaesthesiol Scand. 29:651 1985. 
68. Ruba Hassan. Pretreatment with labetolol reduces propofol injection 
pain. A thesis submitted in partial fulfillment for the requirements of 
the degree of Clinical MD in anaesthesia & Intensive care Feb 2003 
69. Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for 
preventing the pain of injection, Anaesthesia. 43:492 1988. 
70. McCulloch MJ, Lees NW, Assessment and modification of pain on 
induction with propofol (Diprivan). Anaesthesia. 40:1117 1985. 
71. Larsen B, Beerhalter U, Biedler A, Brandt A, Doege F, Brun K, 
Erdkonig R, Larsen R. Less pain on injection by a new formulation 
of propofol? A comparison with propofol LCT, Anaesthesist. 50:842 
2001. 
72.  Smith Graham, Alan R, David J, Text book of anesthesia . In : Smith. 
Intravenous Anasthetic agents (editor), 4th ed. Edinburgh, Churchill 
Livingstone publisher; 2001. p176. 
73. Onaka M, Yamamoto H, Akatsuka M, Mori H, Anesthetic 
management by continuous total intravenous anesthesia; Masui. 
47:1200 1998. 
 79 
74. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in 
drug effects: implications for anesthesiologists. Acta Anaesthesiol 
Scand ;47:241 ,2003. 
 
 
 
 80 
 
 
 
 
 
Appendix 
 81 
University of Khartoum 
Faculty of Medicine 
 
Postgraduate Medical Studies Board 
Department of Anesthesia & intensive care 
 
Data Form 
 
INCIDENCE OF PROPOFOL INDUCED INTRAVENOUS 
INJECTION PAIN 
 
 
 
Serial No  
 
Age                                                 Sex 
 
Size of Cannula: 
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           Severe  
 
 
